Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

Patent metadata

Field	Value
Publication number	US-10857126-B2
Application number	US-201615218663-A
Country	US
Kind code	B2
Filing date	Jul 25, 2016
Priority date	Dec 23, 2010
Publication date	Dec 8, 2020
Grant date	Dec 8, 2020

Abstract

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiment the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

First claim

We claim:

1. A method of improving a cognitive function, comprising:
administering to a subject in need thereof an effective amount of a urolithin thereby improving the cognitive function.

2. The method of claim 1 , wherein the cognitive function is selected from the group consisting of perception, memory, attention, speech comprehension, speech generation, reading comprehension, creation of imagery, learning, and reasoning.

3. The method of claim 2 , wherein the cognitive function is selected from the group consisting of perception, memory, attention, and reasoning.

4. The method of claim 3 , wherein the cognitive function is memory.

5. The method of claim 1 , wherein the urolithin is urolithin A.

6. The method of claim 1 , wherein the urolithin is selected from the group consisting of urolithin A, urolithin B, and a combination of urolithin A and urolithin B.

7. The method of claim 1 , wherein the urolithin is administered orally.

8. The method of claim 1 , wherein the urolithin is administered at least weekly.

9. The method of claim 1 , wherein the urolithin is administered at least daily.

10. The method of claim 1 , wherein the subject is a human.

11. The method of claim 5 , wherein the subject is a human.

12. The method of claim 1 , wherein the urolithin is administered parenterally.

13. The method of claim 1 , wherein the urolithin is administered in the form of a pharmaceutical.

14. The method of claim 1 , where the urolithin is administered in the form of a medical food.

15. The method of claim 1 , wherein the urolithin is administered in the form of a functional food.

16. The method of claim 1 , wherein the urolithin is administered in the form of a food additive.

17. The method of claim 1 , wherein the urolithin is administered in the form of a dietary supplement.

18. The method of claim 1 , wherein the urolithin is administered in the form of a nutritional supplement.

19. The method of claim 1 , wherein the urolithin is administered in the form of a food product.

Assignees

• Amazentis Sa

Inventors

• Rinsch Christopher
• Blanco-Bose William
• Schneider Bernard
• Thomas Charles
• Sandi Carmen
• Auwerx Johan
• Andreux Penelope
• Houtkooper Richardus
• Pirinen Eija
• Mouchiroud Laurent
• Genoux David

Classifications

• A61K36/185

  Magnoliopsida (dicotyledons) · CPC title

• A23V2200/326

  having effect on cardiovascular health · CPC title

• A23L33/105 Primary

  Plant extracts, their artificial duplicates or their derivatives · CPC title

• A61K31/352

  condensed with carbocyclic rings, e.g. methantheline  {(cannabinoids A61K31/658)} · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title